Bristol-Myers Squibb Company (BMY)
Bristol-Myers Stock Up as Q4 Earnings and Revenues Beat Estimates
BMY beats Q4 earnings and revenue estimates as its Growth Portfolio jumps 16%, lifting shares despite continued declines in legacy drugs.
Jobless Claims Pop Up a Bit, Major Morning for Earnings
Jobless Claims notched their highest weekly print since early December, while BMY, RL, COP & more report earnings.
Bristol Myers Just Crushed Earnings, and the Real Catalyst Hasn't Even Hit Yet
Bristol Myers Squibb (NYSE:BMY) reported Q4 2025 revenue of $12.5 billion, essentially flat year-over-year, with full-year 2025 revenue reaching $48.2 billion.
Bristol Myers (BMY) Reports Q4 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Bristol Myers (BMY) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Bristol Myers Squibb (BMY) Tops Q4 Earnings and Revenue Estimates
Bristol Myers Squibb (BMY) came out with quarterly earnings of $1.26 per share, beating the Zacks Consensus Estimate of $1.15 per share. This compares to earnings of $1.67 per share a year ago.
Bristol Myers Stock Rises. Why Fourth-Quarter Earnings Are Exciting Investors.
Bristol Myers Squibb issues an especially upbeat outlook for 2026.
Bristol Myers forecasts upbeat 2026, expecting Eliquis price cut to pay off
Bristol Myers Squibb on Thursday forecast 2026 results above Wall Street estimates, saying that price cuts to its blood thinner Eliquis will help drive up revenue.
Will Reblozyl Shine in Bristol Myers' Fourth-Quarter Results?
BMY leans on fast-growing Reblozyl, now a $2B+ franchise, to fuel results as generics pressure legacy drugs ahead of Q4 earnings.
What's in Store for These 5 Pharma Bigwigs This Earnings Season?
As earnings season accelerates, pharma heavyweights LLY, MRK, NVO, BMY and PFE prepare to reveal their Q4 results amid a strong sector start.
Unveiling Bristol Myers (BMY) Q4 Outlook: Wall Street Estimates for Key Metrics
Evaluate the expected performance of Bristol Myers (BMY) for the quarter ended December 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Should You Buy, Hold, or Sell BMY Stock Ahead of Q4 Earnings?
BMY heads into Q4 2025 earnings with strong Opdivo momentum, even as generic pressure continues to weigh on legacy drug sales.
Will BMY's Oncology Collaborations Drive Its Next Growth Phase?
BMY boosts its oncology pipeline with a Janux deal on tumor-activated therapy, alongside encouraging pumitamig data and multiple cancer collaborations.
